Gilead SEC filing points to possible US FDA warning letter on GMP concerns
This article was originally published in Scrip
Executive Summary
Gilead Sciences said in a recent US Securities and Exchange Commission filing that maintenance and aseptic concerns over manufacturing could land the company with a warning letter from the US FDA.